Drug intelligence / Profile preview

CLL-002

Development stage: Unknown
Lead developer: CELL Technologies
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intralesional

Overview

CLL-002 is an autologous stem cell therapy developed by CELL Technologies for the treatment of degenerative disc disease. As part of the ChondroStem program, CLL-002 utilizes the patient's own bone marrow-derived mesenchymal stem cells (MSCs). The manufacturing process is optimized using the proprietary Oracle AI platform to select and enrich for CD146+ MSCs (enforcing a ≥95% release specification), which exhibit enhanced regenerative and immunosuppressive properties. Administered via intradiscal injection at the point of care, CLL-002 aims to promote tissue regeneration, reduce inflammation, and restore structural quality in the degenerated intervertebral disc. The therapeutic candidate is currently in Phase 2 clinical development.

Brand names: ChondroStem

Beyond the preview

Go deeper on CLL-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLL-002.

Explore the full profile